BRAF and neoplasm: We hypothesised that the combination of BRAF inhibition and anti-PD-1/PD-L1 antibody therapy would improve survival,  that tumour regression would be associated with improved immune-mediated anti-tumour cytotoxicity, and that tumour would eventually recur and show re-emergence of an ineffective immune response.